Cartesian Therapeutics, Inc. Accrued Royalties, Current
Cartesian Therapeutics, Inc. (RNAC) had Accrued Royalties, Current of $2.52 million as of 2023-06-30, per its 10-Q filed 2023-08-17.
Discontinued › Notes › Accrued Liabilities, Current
us-gaap:AccruedRoyaltiesCurrent · last filed 2023-08-17
- 2023-06-30: Accrued Royalties, Current $2.52M.
- 2022-12-31: Accrued Royalties, Current $0.00.
| Period end | Accrued Royalties, Current |
|---|---|
| 2023-06-30 | $2.52M 10-Q · filed 2023-08-17 |
| 2022-12-31 | $0.00 10-Q · filed 2023-08-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |